Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective of this study was to determine the degree to which ramipril and/or rosiglitazone changed β-cell function over time among individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) who participated in the Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) Trial, which evaluated whether ramipril and/or rosiglitazone could prevent or delay type 2 diabetes in high-risk individuals. RESEARCH DESIGN AND METHODS: The present analysis included subjects (n = 982) from DREAM trial centers in Canada who had oral glucose tolerance tests at baseline, after 2 years, and at the end of the study. β-Cell function was assessed using the fasting proinsulin–to–C-peptide ratio (PI/C) and the insulinogenic index (defined as 30–0 min insulin/30–0 min glucose) divided by homeostasis model assessment of insulin resistance (insulinogenic index [IGI]/insulin resistance [IR]). RESULTS: Subjects receiving rosiglitazone had a significant increase in IGI/IR between baseline and end of study compared with the placebo group (25.59 vs. 1.94, P < 0.0001) and a significant decrease in PI/C (−0.010 vs. −0.006, P < 0.0001). In contrast, there were no significant changes in IGI/IR or PI/C in subjects receiving ramipril compared with placebo (11.71 vs. 18.15, P = 0.89, and −0.007 vs. −0.008, P = 0.64, respectively). The impact of rosiglitazone on IGI/IR and PI/C was similar within subgroups of isolated IGT and IFG + IGT (all P < 0.001). Effects were more modest in those with isolated IFG (IGI/IR: 8.95 vs. 2.13, P = 0.03; PI/C: −0.003 vs. −0.001, P = 0.07). CONCLUSIONS: Treatment with rosiglitazone, but not ramipril, resulted in significant improvements in measures of β-cell function over time in pre-diabetic subjects. Although the long-term sustainability of these improvements cannot be determined from the present study, these findings demonstrate that the diabetes preventive effect of rosiglitazone was in part a consequence of improved β-cell function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
β-Cell Glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes.
Robertson, R. P., Harmon, J., Tran, P. O. T., & Poitout, V. (2004) · Diabetes · doi:10.2337/diabetes.53.2007.s119 · Cited by 914
Abdul-Ghani, M. A., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2179 · Cited by 744
Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119562 · Cited by 216
Thiazolidinediones improve β-cell function in type 2 diabetic patients
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00551.2006 · Cited by 200
Mykkanen, L., Haffner, S. M., Hales, C. N., Ronnemaa, T., & Laakso, M. (1997) · Diabetes · doi:10.2337/diabetes.46.12.1990 · Cited by 92
Disturbances in β-Cell Function in Impaired Fasting Glycemia
van Haeften, T. W., Pimenta, W., Mitrakou, A., Korytkowski, M., Jenssen, T., Yki-Jarvinen, H., & Gerich, J. E. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s265 · Cited by 70
Cited by
Curcumin Extract for Prevention of Type 2 Diabetes
Chuengsamarn, S., Rattanamongkolgul, S., Luechapudiporn, R., Phisalaphong, C., & Jirawatnotai, S. (2012) · Diabetes Care · doi:10.2337/dc12-0116 · Cited by 635
Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa863 · Cited by 345
Zinman, B., Harris, S. B., Neuman, J., Gerstein, H. C., Retnakaran, R. R., Raboud, J., Qi, Y., & Hanley, A. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60746-5 · Cited by 235
Self-citationLong-term effect of rosiglitazone and/or ramipril on the incidence of diabetes
DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators (2011) · Diabetologia · doi:10.1007/s00125-010-1985-4 · Cited by 54
“Other analyses also showed that rosiglitazone improved beta cell function [9].”
Result
Metadata
- Authors
- Hanley, A. J., Zinman, B., Sheridan, P., Yusuf, S., Gerstein, H. C., & for the Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) Investigators
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-12-15
- Volume
- 33
- Issue
- 3
- Pages
- 608-613
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2096846676
- Cited by
- 55
- References
- 12
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.